Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + dexamethasone induction therapy in untreated multiple myeloma with renal impairment
2009-010827-23Phase 2Active
- Sponsor
- Fundación PETHEMA
- Start
- Dec 2009
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM) and chronic kidney disease (CKD), sponsored by Fundación PETHEMA. Primary endpoints: Overall response rate and Response kinetics and depth. Started Dec 2009; status: active.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2009-010827-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010827-23.